Skip to Main content Skip to Navigation
Master Thesis

Traitement de la sclérose en plaques par le natalizumab‎ : évaluation des indications, de l'efficacité, de la tolérance, de la qualité de vie et du retentissement médico-économique au sein de la cohorte grenobloise

Abstract : Natalizumab (NTZ), indicated in relapsing-remitting forms of multiple sclerosis (RR-MS), is more effective than treatments used until now. Its rare but serious risks, like progressive multifocal leukoencephalopathy led to restrict the official indications. Objectives of our work were to assess prescription indications, to compare efficacy and tolerance data to those of pivotal studies (AFFIRM and SENTINEL). Then, we focused on assessment of knowledge of patients on NTZ, quality of life (QoL), and medico-economic impact of this prescription. Indications, efficacy, and tolerance of NTZ were assessed retrospectively in University Hospital of Grenoble between 2007 and 2012. Patients' knowledge assessment on NTZ as well as social and professional impact were performed by questionnaires made specifically. Assessment of current quality of life was analyzed by SEP-59 questionnaire, completed by patients treated for more than 18 months, then asking them to complete it about their previous status before treatment introduction. In accordance with MA recommendations, our study confirmed clinical and radiological efficacy of NTZ, well tolerated, as in AFFIRM study. An improvement of general QoL of patients undergoing NTZ, as well as a treatment tendency to limit social and professional consequences of MS has been shown. Finally, knowledge of patients on NTZ was generally good, but more heterogeneous on adverse effects. In short and medium term, NTZ is efficient on inflammatory activity of the RR-MS, and on QoL of patients, well tolerated, and seems to minimize the frequent deterioration of social and professional life induced by MS, with possibly a relatively good cost-effectiveness.
Document type :
Master Thesis
Complete list of metadata

Cited literature [104 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-00733274
Contributor : Jean-Hugues Morneau <>
Submitted on : Tuesday, September 18, 2012 - 12:21:59 PM
Last modification on : Tuesday, May 11, 2021 - 11:36:16 AM
Long-term archiving on: : Friday, December 16, 2016 - 2:05:02 PM

Identifiers

  • HAL Id : dumas-00733274, version 1

Citation

Nathalie Morel. Traitement de la sclérose en plaques par le natalizumab‎ : évaluation des indications, de l'efficacité, de la tolérance, de la qualité de vie et du retentissement médico-économique au sein de la cohorte grenobloise. Médecine humaine et pathologie. 2012. ⟨dumas-00733274⟩

Share

Metrics

Record views

197

Files downloads

5102